- Rare diseases
- Experimental models
- Delivery of therapies
University of California, San Francisco, USA
Lawrence Berkeley National Laboratory, USA
- Nadav Ahituv, USA
- Murim Choi, Korea
- Heon Yung Gee, Korea
- Reetta Hinttala, Finland
- Stanislav Kmoch, Czech Republic
- Saara Laitinen, FInland
- Damian Smedley, UK
- Tomas Stopka, Czech Republic
- Joris van Arensbergen, Netherlands
- Seppo Ylä-Herttuala, Finland
It is my great pleasure to invite you to the fourth CCP Phenogenomics Conference. The conference will be held as a hybrid meeting in 2022. We have returned to BIOCEV campus in Vestec near Prague, where the Czech Centre for Phenogenomics is located, but we also want to give opportunity to join the conference on-line for those who cannot participate physically.
The scientific committee has selected the topic of rare diseases: experimental models & delivery of therapies as the main thematic focus of this year Conference.
We believe that the Conference will provide again an excellent opportunity to support networking and interactions among the researchers, CCP staff, users and experts from the commercial sector.
We are looking forward to meeting you either in Vestec or virtually in September 2022.
Director of the Czech Centre for Phenogenomics
Institute of Molecular Genetics of the Czech Academy of Sciences
Czech Centre for Phenogenomics (CCP)
CCP is a large research infrastructure unique in combining genetic engineering capabilities, advanced phenotyping and imaging modalities, SPF animal housing and husbandry, as well as cryopreservation and archiving, all in one central location – at BIOCEV campus.
Through its membership in INFRAFRONTIER and IMPC, CCP is a partner in a global network that aims to comprehensively and systematically analyze the effect of loss of function gene mutations in mice. The goal is to produce a comprehensive ‘encyclopedia‘ of gene function, that will help identify causative factors of human diseases as well as novel targets for therapeutic intervention.
The conference is organized within the scope of the research programme “Towards Precision Medicine and Gene Therapy” of the Strategy AV21 supported by the Czech Academy of Sciences